ArticleJournal of cardiac failure2013
Protein carbamylation in chronic systolic heart failure: relationship with renal impairment and adverse long-term outcomes.
Article in Journal of cardiac failure, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Metabolomic Profiles and Changes During the 20 Years Preceding Heart Failure.Circulation research · 2026Article
- Potential host-gut microbiota-metabolite associations in cardiorenal syndrome progression: a multi-omics integrative analysis.BMC microbiology · 2026Article
- Age-associated accumulation of carbamylation-derived products in tissues is independent from the myeloperoxidase pathway in mice.PloS one · 2026Article
- Protein carbamylation is associated with increased mortality and CKD progression in patients with CKD: results from the EQUAL study.Clinical kidney journal · 2025Article
- Plasma metabolomics identifies signatures that distinguish heart failure with reduced and preserved ejection fraction.ESC heart failure · 2025Article
- Carbamylated Albumin, Heart Failure, and Mortality in Patients Undergoing Coronary Angiography.Clinical chemistry · 2025Article
- Metabolomics-Based Machine Learning for Predicting Mortality: Unveiling Multisystem Impacts on Health.International journal of molecular sciences · 2024Article
- Comparison of homocitrulline and carbamylated albumin as biomarkers of carbamylation reactions in hemodialyzed patients.Amino acids · 2023Article
- Measurement of Homocitrulline, A Carbamylation-derived Product, in Serum and Tissues by LC-MS/MS.Current protocols · 2023Article
- Avenues for post-translational protein modification prevention and therapy.Molecular aspects of medicine · 2022Review
- Protein carbamylation in end stage renal disease: is there a mortality effect?Current opinion in nephrology and hypertension · 2018Review
- Myeloperoxidase-derived oxidants damage artery wall proteins in an animal model of chronic kidney disease-accelerated atherosclerosis.The Journal of biological chemistry · 2018Article
- Mechanisms and consequences of carbamoylation.Nature reviews. Nephrology · 2017Review
- Metabolic Differences between Dogs of Different Body Sizes.Journal of nutrition and metabolism · 2017Article
- Carbamylated Low-Density Lipoprotein and Thrombotic Risk in Chronic Kidney Disease.Journal of the American College of Cardiology · 2016Article
- Reduction of carbamylated albumin by extended hemodialysis.Hemodialysis international. International Symposium on Home Hemodialysis · 2016Article
- Protein carbamylation and cardiovascular disease.Kidney international · 2015Review
- The Effects of Parenteral Amino Acid Therapy on Protein Carbamylation in Maintenance Hemodialysis Patients.Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2015Article
- Urea and protein carbamylation in ESRD: surrogate markers or partners in crime?Kidney international · 2015Article
- Protein carbamylation in kidney disease: pathogenesis and clinical implications.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundProtein carbamylation, a posttranslational modification promoted during uremia and catalyzed by myeloperoxidase (MPO) at sites of inflammation, is linked to altered protein structure, vascular dysfunction, and poor prognosis. We examine the relationship between plasma protein-bound homocitrulline (PBHCit) levels, a marker of protein lysine residue carbamylation, with cardiorenal function and long-term outcomes in chronic systolic heart failure (HF). METHODS AND
resultsIn 115 patients with chronic systolic HF (left ventricular ejection fraction ≤35%), we measured plasma PBHCit by quantitative mass spectrometry and performed comprehensive echocardiography with assessment of cardiac structure and performance. Adverse long-term events (death, cardiac transplantation) were tracked for 5 years. In our study cohort, the median PBHCit level was 87 (interquartile range 59-128) μmol/mol lysine. Higher plasma PBHcit levels were associated with poorer renal function (estimated glomerular filtration rate [eGFR]: Spearman r = -0.37; P < .001), cystatin C (r = 0.31; P = .001), and elevated plasma amino-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (r = 0.26; P = .006), but not with markers of systemic inflammation or oxidant stress (high-sensitivity C-reactive protein and myeloperoxidase [MPO]: P > .10 for each). Furthermore, elevated plasma PBHCit levels were not related to indices of cardiac structure or function (P > .10 for all examined) except modestly with increased right atrial volume index (r = 0.31; P = .002). PBHCit levels predicted adverse long-term events (hazard ratio [HR] 1.8, 95% confidence interval [CI] 1.3-2.6; P < .001), including after adjustment for age, eGFR, MPO, and NT-proBNP (HR 1.9, 95% CI 1.2-3.1; P = .006).
conclusionsIn chronic systolic HF, protein carbamylation is associated with poorer renal but not cardiac function, and portends poorer long-term adverse clinical outcomes even when adjusted for cardiorenal indices of adverse prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.